as of 12-05-2025 3:43pm EST
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
| Founded: | 2010 | Country: | Switzerland |
| Employees: | N/A | City: | BASEL |
| Market Cap: | 34.8B | IPO Year: | N/A |
| Target Price: | $369.50 | AVG Volume (30 days): | 332.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $170.99 - $385.22 | Next Earning Date: | 11-06-2025 |
| Revenue: | $4,972,687,000 | Revenue Growth: | 53.47% |
| Revenue Growth (this year): | 36.37% | Revenue Growth (next year): | 22.04% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how ONC stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ONC BeiGene Ltd. American Depositary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.